


REMARKS

The title has been amended and a paragraph cross-referencing related applications has been added. The paragraph starting at page 4, line 29 of the English language specification has been amended to recite “The tumor in the Gd-DTPA-enhanced T1-weighted image.” Support for this change is found, for example, at page 4, lines 29-32. The paragraph starting at page 4, line 35 of the English language specification has been amended to recite “Gd-DTPA-enhanced MRI.” Support for this change is found, for example, at page 4, lines 29-36, and at page 32, lines 6-16. The paragraph starting at page 5, line 19 of the English language specification has been amended to recite “hIL2-SeV/ Δ M Δ F vector.” Support for this change is found, for example, at page 34, lines 8-11. The paragraph starting at page 32, line 23 of the English language specification has been amended to recite “anti-CD4” and “anti-CD8.” Support for this change is found, for example, at page 32, lines 23-30. These amendments correct errors in the Japanese specification which are apparent when read in light of the whole context of the translated English specification. Finally, applicants include a sequence listing, based on the sequence listing as filed with WIPO, in which the bibliographic and priority information has been updated. No new matter has been added by the present amendments.

If there are any charges or any credits, please apply them to Deposit Account No.
03-2095.

Respectfully submitted,

Date: JULY 12, 2006



James D. DeCamp, Ph.D.

Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

MICHAEL A. ROBINSON, Ph.D.
REG. NO. 57,903